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ABSTRACT
Background: There has recently been an accumula-
tion of evidence suggesting that endothelial cells (EC)
play a crucial role in the pathogenesis of bronchial
asthma. We examined the prevalence and isotypes of
anti-EC antibodies (AECA) in the sera of children with
asthma and determined the antigenic targets associ-
ated with AECA reactivity.
Methods: Levels of each class of AECA were deter-
mined by cellular ELISA in 156 children with asthma
and in 203 control children. Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and western blot
analysis were performed in samples that contained
high levels of AECA.
Results: In the cellular ELISA, the IgE class of AECA
was detected significantly more frequently in children
with asthma (25/156; 16.0%) than in healthy controls
(2/203; 1.0%; P < 0.01). There were no differences in
the frequencies of detection of IgG, IgA and IgM
classes of AECA between patients and controls. The
IgE–AECA was more frequently detected in younger
children (23/69 vs 2/87 for children younger and
older than 4 years of age, respectively). There was no
correlation between the level of IgE–AECA and that of
total IgE or house dust mite-specific IgE. In western blot
analysis, IgE antibodies against a component of EC
with a molecular mass of 75 kDa were detected in 
20 of 25 patients (80.0%) positive for IgE–AECA, but
they were less frequently detected in patients negative
for IgE–AECA (2/34 (5.9%); P < 0.01).
Conclusions: These results demonstrate that a small
fraction of asthmatic children has IgE–AECA and that
the antigenic target of IgE–AECA is a component of the
EC with a molecular weight of 75 kDa.
Key words: anti-endothelial cell antibodies, bronchial
asthma, IgE.
INTRODUCTION
Airway inflammation characteristic of bronchial asthma 
is the result of eosinophil-dependent tissue injury.1,2
Activated eosinophils release a variety of mediators,
including major basic protein, eosinophilic cationic
protein, eosinophil-derived neurotoxin and eosinophil
peroxidase, which are damaging to the airway epithe-
lium.3,4 Eosinophils also produce leukotrienes, which
induce airway smooth muscle contraction and airway
edema.5 Because inflammatory cells have to cross the
endothelial wall to access the inflammatory site, upregu-
lation of adhesion molecules on endothelial cells (EC) is
an important feature.
Upregulation of intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1),
and sulfated the sialyl Lewis X glycans on airway endothe-
lium has been observed in patients with asthma.6,7
Moreover, serum levels of soluble adhesion molecules,
including soluble ICAM-1, soluble E-selectin and soluble
VCAM-1, are increased in patients with bronchial
asthma.8–10 In fact, it is widely accepted that an increased
expression of cell surface adhesion molecules is followed
by the release of their soluble forms into the circulation.
Because E-selectin expression is restricted to EC,
increased levels of soluble E-selectin in asthma means
endothelial damage or activation.11
Anti-endothelial cell antibodies (AECA) were detected
in the sera from patients with a variety of conditions 
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associated with vascular injuries.12 Anti-endothelial cell
antibodies play a role in pathophysiology by inducing
activation of EC, resulting in upregulation of the expres-
sion of endothelial adhesion molecules and secretion of
chemoattractants and cytokines.13–16 The antigenic tar-
gets associated with reactivity of AECA have not been
clearly defined, but a range of antigenic sites may be
involved.17 Little is known about the distribution of AECA
and the antigenic targets of EC in patients with asthma,
particularly in children with asthma.18
The purpose of the present study was to determine the
prevalence and isotypes of AECA in asthmatic children
and the antigenic targets associated with reactivity of
AECA.
METHODS
Patients
Sera were collected from 156 patients with asthma (84
males and 72 females) aged from 6 months to 15 years
(mean (±SD) age 5.0 ± 3.8 years) and 206 normal
healthy children (109 males and 97 females) aged from
6 months to 15 years (mean age 7.5 ± 3.9 years). There
was no significant difference between the ages of the
patients and the control subjects. Asthma was diagnosed
on the basis of a history of episodic wheezing. The
patients enrolled in the study were in a stable condition,
with neither dyspnea nor wheeze. Symptoms of asthma
were controlled by medications. Of 156 patients with
asthma, 11 patients were receiving treatment with anti-
histamine drugs only, seven were receiving treatment with
oral leukotriene receptor antagonists (LTRA), three were
receiving treatment with inhaled disodium cromoglycate
(DSCG) and 41 were receiving treatment with theo-
phylline. Twenty-four patients were receiving treatment
with theophylline and LTRA, 11 were receiving treatment
with theophylline and DSCG, 51 were receiving treat-
ment with theophylline, DSCG and inhaled β2-adrenergic
receptor agonists, three were receiving treatment with
theophylline and inhaled beclomethasone (ICS), three
were receiving treatment with theophylline, DSCG and
ICS, and two were receiving treatment with theophylline,
inhaled β2-adrenergic receptor agonists, DSCG and ICS.
None of the patients was on oral corticosteroid or immuno-
suppressive drugs at the time of blood collection. In some
patients, serum was also obtained during exacerbation 
of asthma. Of 156 asthmatic children, 146 patients
(93.6%) were atopic and 10 (6.4%) were non-atopic.
Patients were considered as atopic when they had atopic
dermatitis, allergic rhinitis, allergic family history, high
total IgE titer or high IgE titer specific for mite allergens.
Sixty-nine patients (44.2%) had mild disease, 51 (32.7%)
had moderate disease and 36 (23.1%) had severe
disease. The grade of severity was determined according
to the Japanese Guideline for Asthma.19 All sera were
aliquoted and stored at – 20°C.
Cell isolation
Endothelial cells were obtained from human umbilical
veins using methods described previously.20 Recovered
EC were grown to confluence in type I collagen (Sigma,
St Louis, MO, USA)-coated flasks in RPMI 1640 medium
with 20% fetal calf serum, 25 µg/mL endothelial cell
growth supplement (Sigma) and 30 U/mL heparin. At this
stage, the cells were detached by exposure to trypsin and
EDTA and were washed three times with phosphate-
buffered saline (PBS).
Cellular ELISA for detection of AECA
Immunoglobulin classes of AECA were determined by a
cellular enzyme immunoassay as described previously.12
Briefly, EC were transferred to 96-well type I collagen-
coated flat-bottomed plates at a density of 1–2 × 104
cells/well and were grown to confluence. In all experi-
ments, a pool of at least three different donors at the first
passage was used. After washing twice with PBS, 100 µL
of 2% bovine serum albumin (BSA) in PBS was added 
to each well and the plates were left for 1 h at room 
temperature to reduce non-specific binding of immuno-
globulins. After three washes with PBS, 100 µL serum
sample diluted with PBS was added to each well in tripli-
cate and the plates were left for 1 h at room temperature.
Several wells containing diluent only were used to provide
a background binding level. Sera were routinely diluted
1 : 400 for IgG-AECA, 1 : 300 for IgM-AECA, 1 : 100
for IgA-AECA and 1 : 100 for IgE-AECA because, in 
preliminary studies, it was found that these dilutions 
gave the best discrimination between binding activity 
in the reference serum and that in normal control serum.
In each assay, serum that has been obtained from a
patient with systemic lupus erythematosus was used as 
a positive control. Bound immunoglobulin was detected
by peroxidase-conjugated goat antihuman class-specific
immunoglobulin (MBL, Tokyo, Japan). Results are expressed
as a binding index (BI) calculated as:
BI = 100 × (S – B)/(P – B)
where S is the absorbance of the sample, P is the absorb-
ance of the positive control and B is the absorbance of
background binding.12 Values are the mean of three
replicate determinations. A BI value of more than 3SD
above the average BI of the healthy controls was consid-
ered positive. Interassay variation was determined by
testing seven replicates of a serum sample positive for
AECA. The variation coefficients were 9.5, 11.2, 10.5
and 11.5% for IgG, IgA, IgM, and IgE classes of AECA,
respectively. The intra-assay variation was evaluated by
testing six serum samples positive for AECA. The variation
coefficients were 5.5, 7.2, 8.5 and 8.3% for IgG, IgA,
IgM, and IgE classes of AECA, respectively.
Western blot analysis for detection of
IgE–AECA
Endothelial cells were lysed at approximately 1 × 106
/mL in NP-40 lysis buffer consisting of 0.5% NP-40, 
1% aprotinin, 1 mmol/L diisopropyl fluorophosphate,
5 mmol/L iodoacetamide and 1 mmol/L phenylmethane
sulfonyl fluoride. After mixing gently, the cells were kept
on ice for 30 min and then centrifuged at 1600 g for
15 min at 4°C. The supernatant was kept at – 80°C until
use. Cell lysates were separated by 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
in a reducing condition and the separated proteins were
transferred to polyvinilidene difluoride (PVDF) mem-
branes (Amersham-Pharmacia, Uppsala, Sweden). The
blots were incubated for 1 h at room temperature in PBS
with 2% BSA. Strips of PVDF membrane were then 
incubated for 1 h with sera from the patients and controls
that had been diluted with PBS in the same manner as
that of cellular ELISA. After four washes with PBS, the
strips were incubated for 1 h at room temperature with
peroxidase-conjugated goat antihuman IgE-specific anti-
body (MBL). After a further four washes, bound peroxi-
dase conjugates were detected using a Peroxidase Stain
Kit for Immunoblotting (Nacalai Tesque, Kyoto, Japan).
Statistical analysis
Statistical significance of differences between groups was
tested by the Mann–Whitney U-test. The χ2-test was used
to compare proportions between two groups. Spearman’s
rank coefficient was used to evaluate correlation between
two groups. All tests were accepted as statistically signifi-
cant if P < 0.05.
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Fig. 1 (a) Comparison of serum levels of IgE–anti-endothelial cell antibodies (AECA) between patients with asthma and those
without asthma (normal controls). Serum levels of IgE–AECA were significantly (P < 0.001) higher in children with asthma
(n = 156;72.7 ± 61.6%) than in children without asthma (n = 206; 31.5 ± 26.8%). (b) Age distribution of IgE–AECA in children
with asthma. Patients aged 0–1 years had significantly higher levels of IgE–AECA than patients aged 2–3 years (118.3 ± 64.4 vs
102.6 ± 76.1, respectively; P < 0.001) and each age group above 4 years (*P < 0.0001). Similarly, patients aged 2–3 years had
significantly higher levels of IgE–AECA than each age group above 4 years (**P < 0.001).
RESULTS
Determination of the prevalence of AECA in
children with asthma by cellular ELISA
A significantly higher BI titer for IgE–AECA was found in
children with asthma than in normal controls (mean
(±SD) 72.7 ± 61.6 vs 31.5 ± 26.8%, respectively;
Fig. 1a). When a BI value greater than the mean + 3SD
of normal serum samples was used as the lower limit for
detecting positive binding, IgE–AECA was observed in
only two of 203 normal serum samples (1.0%). In con-
trast, 25 of 156 patients with asthma (16.0%) had signif-
icantly high levels of IgE–AECA (P < 0.01).
We then investigated the relationship between IgE–AECA
and various clinical parameters. With regard to patient
age, the levels of IgE–AECA were highest in the younger
age groups (Fig. 1b). Twenty-three of 69 children with
asthma under 4 years of age (33.3%) exhibited positive
IgE–AECA. In contrast, significantly high levels of IgE–AECA
were detected in only two of 87 asthmatic children over
4 years of age (2.3%). No significant association was
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Fig. 2 Relationship between the levels of IgE–anti-endothelial cell antibodies (AECA) and various clinical features of the patients.
No significant association was found between the levels of IgE–AECA and other specific clinical features of asthmatic children,
including type of asthma (a), sex of the patients (b), severity of disease (c), medications used for the treatment of asthma (d) and 
exacerbation of disease (e). None, antihistaminic drugs only; L, leukotriene receptor antagonists (LTRA); C, inhaled disodium 
cromoglycate (DSCG); T, theophylline; TL, theophylline and LTRA; TC, theophylline and DSCG; TCB, theophylline, DSCG and
inhaled β2-adrenergic receptor agonists; TS, theophylline and inhaled beclomethasone (ICS); TCS, theophylline, DSCG and ICS;
TCBS, theophylline, DSCG, inhaled β2-adrenergic receptor agonists and ICS.
found between the presence of IgE–AECA and other 
specific clinical features of asthmatic children, including
type of asthma (Fig. 2a), sex of the patients (Fig. 2b),
severity of disease (Fig. 2c) and medications used for 
the treatment of asthma (Fig. 2d). We then compared the
levels of IgE–AECA within individual patients who showed
high IgE–AECA levels when they were asymptomatic
compared with levels during acute exacerbation (n = 25).
The levels of IgE–AECA did not show any changes with
exacerbation (Fig. 2e).
The detection of IgE–AECA was evaluated according
to the clinical characteristics of the children with asthma
(Table 1). The IgE–AECA were detected mainly in
younger children with asthma (P < 0.01), in patients with
low serum IgE levels (P < 0.01) and in patients with low
serum mite-specific IgE (P < 0.01). The serum level of
IgE–AECA was not correlated with either total serum IgE
or house dust mite-specific IgE.
There were no differences between BI titers for other
classes of AECA in children with asthma and normal 
controls (IgG-AECA: 37.2 ± 7.6 vs 36.0 ± 8.7%,
respectively; IgA-AECA: 39.0 ± 9.2 vs 36.5 ± 7.7%,
respectively; IgM-AECA: 43.7 ± 5.9 vs 42.9 ± 6.5%,
respecitvely). None of the patients or controls exhibited a
BI titer of more than the mean + 3SD of normal serum
samples for IgG–, IgA– and IgM–AECA
Detection of IgE–AECA to the 75 kDa EC 
antigen in asthmatic patients positive for
AECA
To determine the antigen targets associated with reactivity
of IgE–AECA, SDS-PAGE followed by western blot analy-
sis was performed in 25 asthmatic children who showed
significantly high serum levels of IgE–AECA by cellular
ELISA. Although multiple antigens were detected by
serum antibodies of the patients, recurrent binding to
human umbilical vein endothelial cells antigens at
approximately 75 kDa was evident in samples from 20
asthmatic children positive for IgE–AECA (80.0%; Fig. 3).
Anti-75 kDa antigen antibodies were detected in two of
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Table 1 Clinical features of children with asthma positive for IgE–anti-endothelial cell antibodies
Absence of IgE–AECA Presence of IgE–AECA P
No. patients 131 25
Age (years) 5.7 ± 3.8 1.8 ± 1.6 < 0.01
Sex ratio (females/males) 60/71 12/13 NS
Atopic dermatitis (n) 64/131 14/25 NS
Percentage 48.9 56.0
Total IgE (IU/mL) 475 ± 560 194 ± 248 < 0.01
Mite-specific IgE (score) 4.0 ± 1.9 2.4 ± 2.0 < 0.01
Detection of anti-75 kDa antibody (n) 2/34 20/25 < 0.01
Percentage 5.9 80.0
Where appropriate, data are given as the mean±SD.
AECA, anti-endothelial cell antibodies.
Fig. 3 Binding of serum antibodies to the 75 kDa endothelial
cell antigen in asthmatic children. Endothelial cell lysates were
resolved by 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and were blotted onto polyvinilidene difluoride
(PVDF) membranes. After being blocked with 2% bovine serum
albumin, the membrane strips were incubated with diluted sera
that contained high levels of IgE–anti-endothelial cell anti-
bodies and those did not. The bound IgE antibodies were
detected by peroxidase-conjugated anti-IgE antibody. Binding
at 120 and 20 kDa was non-specific, because these bands
were detected in all serum samples. PT, patients; Co, controls.
34 asthmatic children with normal levels of IgE–AECA
(5.9%) and in none of 25 normal control children (0.0%;
P < 0.01).
DISCUSSION
The present study demonstrated, for the first time, a high
prevalence of IgE class AECA in sera from younger chil-
dren with asthma, but not in sera from older children with
asthma. The IgE–AECA were detected in 33.3% of asth-
matic children under 4 years of age, but in only 2.3% of
asthmatic children over 4 years of age. Because the
serum level of IgE tends to increase with age, no correla-
tion was found between the level of IgE–AECA and
that of total IgE or between the level of IgE–AECA 
and that of house dust mite-specific IgE. This suggests
that the reactivity against EC antigens in sera from 
children with asthma seems to be a specific immune
response. The existence of a specific IgE antibody against
the 75 kDa antigen of EC in asthmatic children who
exhibited increased levels of IgE–AECA further supports
this hypothesis.
The distribution of each class of AECA in children with
asthma is quite different from that in adults with asthma.
Lassalle et al. repoted that IgG–AECA were found in
approximately one-third of adult patients with asthma,
whereas IgE–AECA were detected in only 2.0% of
patients.18 In their study, patients with AECA were mainly
non-atopic, had more severe asthma and tended to have
aspirin-sensitive asthma. In contrast, in the present study,
the IgE class of AECA was frequently detected in younger
children with asthma and IgG–AECA was not detected in
any asthmatic children. The levels of IgE–AECA were not
influenced by other clinical features of asthma, including
type of asthma, sex of the patients, severity of disease and
medications used for the treatment of asthma. The differ-
ent distribution of IgG–AECA in children and adults 
with asthma seems to be a result of differences in the 
features of asthma. Adult asthma is usually non-atopic
and more severe than that in children and it usually
occurs in middle age.21 In contrast, epidemiologic studies
have shown that aspirin-sensitive asthma is rarely
observed in children.22,23 Above all, asthma in childhood
is closely linked with atopy, which is a genetic pre-
disposition with increased IgE production.22 It is therefore
possible that the difference in immunoglobulin classes of
AECA between adults and children with asthma is due to
this genetic background.
While AECA are directed against a heterogeneous
family of surface endothelial proteins,24 the results of the
present study have revealed that a 75 kDa component of
EC is the target of IgE–AECA in asthmatic children. The
antigenic targets associated with reactivity of AECA have
not been clearly defined, but it has been shown that there
is a heterogeneous range of endothelial antigens.24
However, the frequent detection of anti-75 kDa antigen
antibodies in sera that contain high titers of IgE–AECA
suggests that the 75 kDa protein on EC is the main target
of IgE–AECA in asthmatic children. In adult patients with
asthma, IgG–AECA against a 55 kDa antigen shared by
platelets and EC has been detected.18 The difference
between the antigenic targets of AECA in children and
adults is thought to strongly influence differences in the
class and the distribution of AECA. Further investigations
are needed to elucidate the nature of the 75 kDa antigen
on EC.
The function and role of IgE–AECA in asthmatic 
children remain unclear. By analogy to the function of
IgG–AECA, it is possible that IgE–AECA induce adher-
ence of leukocytes that have receptors for IgE, including
basophils, eosinophils,25 platelets26 and monocytes,27 on
EC. At the same time, cross-linkage of FcεRI on these
cells could lead to activation of these cells, release of
mediators and production of various cytokines that
directly act on adjacent EC. These speculations are in
accordance with the pathophysiology of bronchial asthma
in childhood.28 However, further investigations are needed
to determine whether IgE–AECA are involved in the
pathogenesis of bronchial asthma.
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